Ga onbeperkt met Magzter GOLD
Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts
Poging GOUD - Vrij
Does US cancer drug nod make Cipla attractive?
Mint Hyderabad
|April 18, 2025
Cipla, which makes HIV, respiratory and cancer drugs, is targeting North America with generic launches
Cipla Ltd's shares have surged 6% since last week when it announced the final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug. Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs loom?
"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."
Dit verhaal komt uit de April 18, 2025-editie van Mint Hyderabad.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Hyderabad
Mint Hyderabad
Cyberattack on vendor hits major US banks
Client data for JPMorgan Chase, Morgan Stanley Citi and other major banks may have been accessed in a hack of a tech vendor, The New York Times reported on Saturday, citing people familiar with the matter.
1 min
November 24, 2025
Mint Hyderabad
Walmart was once demonized but has transformed its image
Its staff-oriented strategy faced investor scepticism but has paid off
3 mins
November 24, 2025
Mint Hyderabad
India to curb antibiotic use in animals to control drug resistance
India has unveiled its next-generation national action plan on antimicrobial resistance (AMR 2.0) for 2025-2029, to curb misuse of antibiotics across humans and animals as drug-resistant infections emerge as a major national health threat.
2 mins
November 24, 2025
Mint Hyderabad
Amfi leads data drive as Sebi plans fee cap
The mutual fund industry is compiling an extensive dataset on portfolio churn and transaction costs to help the Securities and Exchange Board of India (Sebi) evaluate its proposal to sharply cap brokerage fees.
2 mins
November 24, 2025
Mint Hyderabad
Carlyle targeting $300 mn side fund
Carlyle Group Inc. is launching an India side fund to operate along the firm’s sixth pan-Asia investment vehicle, to tap opportunities in everything from tech to health care.
1 min
November 24, 2025
Mint Hyderabad
Embrace the quiet joy of doing nothing in retirement
In a world demanding constant action, finding stillness is the perfect, complementary antidote to an active retirement
3 mins
November 24, 2025
Mint Hyderabad
CAG plans shift to live audits to curb public funds misuse
The overhaul is designed to flag tendering lapses, execution delays and potential losses early
2 mins
November 24, 2025
Mint Hyderabad
'Stay invested in the stock market, everything is for the long haul'
Veteran value investor Ramesh Damani is ignoring doomsday warnings about a US tech stock correction and noises surrounding corporate earnings growth trajectory back home, staying loyal instead to his credo of long-term investments, using a bottom -up approach. He remains unconcerned about short term market corrections, advising investors to
5 mins
November 24, 2025
Mint Hyderabad
BirlaNu announces new Andhra plant
Building materials and home solutions company BirlaNu on Sunday announced plans to set up a greenfield fibre cement board plant in Nellore district of Andhra Pradesh.
1 min
November 24, 2025
Mint Hyderabad
OYO Assets gets 125 cr fresh funds
OYO parent PRISM-backed OYO Assets has raised ₹125 crore in a fresh funding round from a clutch of institutional and private investors led by InCred, people aware of the development said.
1 min
November 24, 2025
Listen
Translate
Change font size